Chad M. Robins, CEO and Chairman at Adaptive Biotechnologies Corp (ADPT), sold 321,468 shares at $18.94 ($6.1M) on 2025-12-01, disclosed to the SEC on 2025-12-01.
Scheduled sale ($6.1M) by CEO and Chairman under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.68 | 35,736 | $703K | 11.5% |
| 2 | $19.68 | 35,736 | $703K | 11.5% |
| 3 | $18.94 | 124,998 | $2.4M | 38.5% |
| 4 | $18.94 | 124,998 | $2.4M | 38.5% |
| Total | $19.10 avg | 321,468 | $6.1M | 100% |
| Filing → |
| ADPT | SELL | 2026-03-13 | $6.2M | — | Filing → |
| ADPT | SELL | 2026-03-03 | $8.3M | — | Filing → |
| ADPT | SELL | 2026-02-04 | $2.3M | — | Filing → |